Video Experimental Relacionado
Updated: Jun 27, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Fenotipo, diagnóstico y tratamiento de la enfermedad de Gaucher
1Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
Lancet (London, England)
|December 20, 2008
Resumen
La investigación de la enfermedad de Gaucher avanza en la medicina molecular, estableciendo la efectividad de la terapia enzimática para las manifestaciones viscerales. Las innovaciones apuntan a tratamientos rentables para las variantes neuronopáticas y otros trastornos genéticos.
Área de la Ciencia:
- La medicina molecular es una medicina molecular.
- Genética La genética.
- La bioquímica es la bioquímica.
Sus antecedentes:
- La enfermedad de Gaucher sirve como un modelo clave para comprender las aplicaciones de la medicina molecular.
- Los análisis extensos han identificado diversas variantes de la enfermedad y han establecido correlaciones genotipo-fenotipo.
Objetivo del estudio:
- Revisar los avances en la investigación de la enfermedad de Gaucher, centrándose en la medicina molecular.
- Para resaltar la eficacia de la terapia enzimática y explorar nuevas estrategias de tratamiento.
Principales métodos:
- Análisis de datos de miles de personas con enfermedad de Gaucher.
- Revisión de las estrategias terapéuticas actuales y emergentes, incluida la terapia enzimática, el agotamiento del sustrato y los acompañantes farmacológicos.
Principales resultados:
- La terapia enzimática inhibe eficazmente o invierte la progresión de la enfermedad visceral.
- La comprensión de las variaciones étnicas, el pronóstico y los resultados ha mejorado.
- Las nuevas estrategias terapéuticas son prometedoras para las variantes neuronopáticas.
Conclusiones:
- La medicina molecular ha mejorado significativamente el diagnóstico y el tratamiento de la enfermedad de Gaucher.
- Las terapias novedosas, incluyendo el agotamiento del sustrato y las estrategias de acompañamiento, ofrecen potencial para una aplicación más amplia y rentabilidad.
- Estos avances benefician a los pacientes con enfermedad de Gaucher y otros trastornos lisosómicos y genéticos.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:35Pedigree Analysis
Overview
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...